Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT03289962	TitleA Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors	Phase Phase 1	Date Added 2017-09-21	Location Arizona, United States California, United States Colorado, United States Connecticut, United States Massachusetts, United States Nevada, United States New York, United States Oklahoma, United States Oregon, United States Tennessee, United States Washington, United States Belgium Canada Germany Netherlands Spain Sweden United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Atezolizumab, Autogene cevumeran, Tecentriq	Tags MSS/ MMRp
NCT ID NCT04595266	TitleChemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease	Phase Phase 2	Date Added 2020-10-20	Location Spain	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Anti-EGFR or Bevacizumab, FOLFOX regimen, LIVERPEARLS-Irinotecan	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03310008	TitleDose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases	Phase Phase 1	Date Added 2017-10-16	Location Belgium	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs NKR-2 cells	Tags MSS/ MMRp
NCT ID NCT03673787	TitleA Trial of Ipatasertib in Combination With Atezolizumab	Phase Phase 1, Phase 2	Date Added 2018-09-17	Location United Kingdom	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs Atezolizumab, Ipatasertib	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03155061	TitleStudy of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors	Phase Phase 1	Date Added 2017-05-16	Location Japan	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs ONO-4538, ONO-4578, Opdivo	Tags MSS/ MMRp
NCT ID NCT04591431	TitleThe Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy	Phase Phase 2	Date Added 2020-10-19	Location Italy	Prior IO Allowed No	CRC-directed No	Status Active, not recruiting	Drugs Alectinib, Atezolizumab, Brigatinib, Cobimetinib, Entrectinib, Erlotinib, everolimus, Ipatasertib, Ipilimumab, Itacitinib, Lapatinib, Nivolumab, Oncology Drugs, palbociclib, Pemigatinib, Pertuzumab, Ponatinib, Trastuzumab, Trastuzumab emtansine, Vemurafenib, Vismogedib	Tags MSS/ MMRp
NCT ID NCT04130854	TitleINNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer	Phase Phase 2	Date Added 2019-10-18	Location Arizona, United States North Carolina, United States Oregon, United States Texas, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days, mFOLFOX and Radiation Therapy 5Gy x 5 days	Tags MSS/ MMRp
NCT ID NCT02617277	TitleSafety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours	Phase Phase 1	Date Added 2015-11-30	Location Colorado, United States Florida, United States Tennessee, United States	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs AZD1775, MEDI4736	Tags MSS/ MMRp
NCT ID NCT03475004	TitleStudy of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer	Phase Phase 2	Date Added 2018-03-23	Location Colorado, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Pembrolizumab, Bevacizumab, and Binimetinib	Tags MSS/ MMRp
NCT ID NCT04940546	TitleNeoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients	Phase Phase 1, Phase 2	Date Added 2021-06-25	Location China	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Bevacizumab, capecitabine, oxaliplatin, Sintilimab	Tags MSS/ MMRp

Showing 261 to 270 of 299 entries